Cargando…
SimVec: predicting polypharmacy side effects for new drugs
Polypharmacy refers to the administration of multiple drugs on a daily basis. It has demonstrated effectiveness in treating many complex diseases , but it has a higher risk of adverse drug reactions. Hence, the prediction of polypharmacy side effects is an essential step in drug testing, especially...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327181/ https://www.ncbi.nlm.nih.gov/pubmed/35883105 http://dx.doi.org/10.1186/s13321-022-00632-5 |
_version_ | 1784757452097454080 |
---|---|
author | Lukashina, Nina Kartysheva, Elena Spjuth, Ola Virko, Elizaveta Shpilman, Aleksei |
author_facet | Lukashina, Nina Kartysheva, Elena Spjuth, Ola Virko, Elizaveta Shpilman, Aleksei |
author_sort | Lukashina, Nina |
collection | PubMed |
description | Polypharmacy refers to the administration of multiple drugs on a daily basis. It has demonstrated effectiveness in treating many complex diseases , but it has a higher risk of adverse drug reactions. Hence, the prediction of polypharmacy side effects is an essential step in drug testing, especially for new drugs. This paper shows that the current knowledge graph (KG) based state-of-the-art approach to polypharmacy side effect prediction does not work well for new drugs, as they have a low number of known connections in the KG. We propose a new method , SimVec, that solves this problem by enhancing the KG structure with a structure-aware node initialization and weighted drug similarity edges. We also devise a new 3-step learning process, which iteratively updates node embeddings related to side effects edges, similarity edges, and drugs with limited knowledge. Our model significantly outperforms existing KG-based models. Additionally, we examine the problem of negative relations generation and show that the cache-based approach works best for polypharmacy tasks. |
format | Online Article Text |
id | pubmed-9327181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-93271812022-07-28 SimVec: predicting polypharmacy side effects for new drugs Lukashina, Nina Kartysheva, Elena Spjuth, Ola Virko, Elizaveta Shpilman, Aleksei J Cheminform Methodology Polypharmacy refers to the administration of multiple drugs on a daily basis. It has demonstrated effectiveness in treating many complex diseases , but it has a higher risk of adverse drug reactions. Hence, the prediction of polypharmacy side effects is an essential step in drug testing, especially for new drugs. This paper shows that the current knowledge graph (KG) based state-of-the-art approach to polypharmacy side effect prediction does not work well for new drugs, as they have a low number of known connections in the KG. We propose a new method , SimVec, that solves this problem by enhancing the KG structure with a structure-aware node initialization and weighted drug similarity edges. We also devise a new 3-step learning process, which iteratively updates node embeddings related to side effects edges, similarity edges, and drugs with limited knowledge. Our model significantly outperforms existing KG-based models. Additionally, we examine the problem of negative relations generation and show that the cache-based approach works best for polypharmacy tasks. Springer International Publishing 2022-07-26 /pmc/articles/PMC9327181/ /pubmed/35883105 http://dx.doi.org/10.1186/s13321-022-00632-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Methodology Lukashina, Nina Kartysheva, Elena Spjuth, Ola Virko, Elizaveta Shpilman, Aleksei SimVec: predicting polypharmacy side effects for new drugs |
title | SimVec: predicting polypharmacy side effects for new drugs |
title_full | SimVec: predicting polypharmacy side effects for new drugs |
title_fullStr | SimVec: predicting polypharmacy side effects for new drugs |
title_full_unstemmed | SimVec: predicting polypharmacy side effects for new drugs |
title_short | SimVec: predicting polypharmacy side effects for new drugs |
title_sort | simvec: predicting polypharmacy side effects for new drugs |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327181/ https://www.ncbi.nlm.nih.gov/pubmed/35883105 http://dx.doi.org/10.1186/s13321-022-00632-5 |
work_keys_str_mv | AT lukashinanina simvecpredictingpolypharmacysideeffectsfornewdrugs AT kartyshevaelena simvecpredictingpolypharmacysideeffectsfornewdrugs AT spjuthola simvecpredictingpolypharmacysideeffectsfornewdrugs AT virkoelizaveta simvecpredictingpolypharmacysideeffectsfornewdrugs AT shpilmanaleksei simvecpredictingpolypharmacysideeffectsfornewdrugs |